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Abstract
Choroideremia (CHM) is an X-linked retinal degenerative disease resulting from a lack of functional Rab Escort Protein-1 (REP-
1). As a ﬁrst step in developing gene-based therapies for this disease, we evaluated the feasibility of delivering functional REP-1 to
defective lymphocytes and ﬁbroblasts isolated from individuals with CHM. A recombinant adenovirus delivering the full-length
human cDNA encoding REP-1 under the control of a cytomegalovirus promoter was generated. Adenovirus-mediated delivery of
REP-1 rescued the defective cells as assessed through protein and enzymatic assays. Ultimately, it may be possible to use virus-
mediated delivery of REP-1 to evaluate disease intervention in vivo.
 2002 Elsevier Science Ltd. All rights reserved.
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1. Introduction
Choroideremia or tapeto-choroidal dystrophy (CHM;
MIM # 303100, (McKusick, 1994)) is a common form
of X-linked recessive retinal degeneration. It is one of
the few hereditary retinal degenerations that can be
speciﬁcally identiﬁed by clinical examination of the ret-
ina (Sorsby, Franceshetti, Joseph, & Davey, 1952).
Mottled areas of pigmentation are apparent in fundus
examination in aﬀected children and female carriers. By
adolescence, aﬀected males display scalloped areas of
conﬂuent loss of retinal pigment epithelium (RPE) and
choriocapillaris. These changes are readily apparent on
standard ophthalmoscopy and can be conﬁrmed by
pathognomic ﬁndings on ﬂuorescein angiography. The
changes often result in total blindness by the third or
fourth decade. Heterozygous females, in contrast, have
no or milder symptoms, probably dependent on the
degree of X chromosome inactivation. Female carriers
can, however, be reliably identiﬁed by ophthalmoscopy
(Karna, 1986).
At present, there is neither a treatment nor a cure for
CHM. There are several reasons, however, why this
disease may be a good candidate for gene therapy
studies: (1) The complete human cDNA implicated in
CHM has been identiﬁed and cloned. This gene encodes
Rab Escort Protein 1 (REP-1) (van Bokhoven et al.,
1994a). REP-1 is a protein which escorts the Rab pro-
teins during and after their prenylation to intracellular
membranes (Alexandrov, Horiuchi, Steele-Mortimer,
Seabra, & Zerial, 1994; Andres et al., 1993; Seabra,
Brown, Slaughter, Sudhof, & Goldstein, 1992). This
protein also plays an important role in the prenylation
reaction itself in retinal tissues as it is indispensable for
the activity of Rab geranylgeranyl transferase (Rab
GGTase); (2) The disease is caused by a lack of a
functional gene product. At least 15 diﬀerent small
mutations (i.e., involving only 1–4 nucleotides) have
been identiﬁed so far in the gene encoding REP-1. All of
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the REP-1 mutations identiﬁed so far in aﬀected indi-
viduals are predicted to lead to premature stops during
translation and to result either in a protein truncated at
the carboxy-terminus or in no protein at all (Sankila,
Tolvanen, van den Hurk, Cremers, & de la Chapelle,
1992; Schwartz, Rosenberg, van den Hurk, van depol, &
Cremers, 1993; van Bokhoven et al., 1994b; van den
Hurk et al., 1992); (3) CHM is one of the few retinal
degenerative diseases in which the defective gene can be
identiﬁed upon clinical examination. Thus, a large
population of aﬀected individuals with this particular
gene defect is already available; (4) While carriers of this
disease are identiﬁable clinically, they suﬀer minimal
symptoms. Thus, addition of the wild type version of
REP-1 should result in rescue of the diseased cells; and
(5) REP-1 is normally expressed in other tissues besides
retinal cells. Such tissues (lymphocytes, ﬁbroblasts, for
example) from individuals with CHM appear normal
otherwise, probably due to the ability of a second REP
protein, REP-2, to carry out the necessary functions in
these cells (Cremers, Armstrong, Seabra, Brown, &
Goldstein, 1994; Seabra, 1996). Lymphocytes and ﬁ-
broblasts, unlike retinal tissue, can be harvested non-
invasively and cultured for extended periods of time.
Therefore, they are well-suited for in vitro rescue stud-
ies.
In the present study, we generated and puriﬁed a re-
combinant adenovirus carrying the cDNA encoding
human REP-1 and tested the ability of this virus to
rescue ﬁbroblasts and transformed lymphocytes from
individuals aﬀected with CHM. Rescue was assessed
through protein studies (Western blots and immuno-
ﬂuorescence) and functional assay.
2. Materials and methods
2.1. Human tissues
Samples from aﬀected individuals, carriers and unaf-
fected individuals from two diﬀerent families with CHM
were used. Samples were obtained by venipuncture and/
or skin biopsy after informed consent had been ob-
tained. In the ﬁrst family, a premature stop codon
(Arg555! stop) mutation leads to a carboxy-terminal
truncation of 99 amino acids (Fujita, Skolnick, Pastkis,
Yang Fen, & Swaroop, 1995). Cells from an aﬀected
individual in this family are identiﬁed here as CPF1. In
the second family, there is an X chromosome deletion of
250 Kb in the CHM locus (Cremers et al., 1990a). Cells
from an aﬀected individual are identiﬁed as CPF2.
Aliquots of white blood cells were used either for
DNA extraction or to generate transformed lympho-
blasts. Lymphoblasts were transformed using Epstein
Barr virus and cultured in RPMI 1640 containing 20%
fetal bovine serum (FBS), 2% L-glutamine, 1% oxalo-
acetate-pyruvate-bovine insulin (OPI) media supple-
ment and 20 ml/ml phytohemagluttinin (Life Tech-
nologies Inc.; Gaithersburg, MD), 20 U/ml of IL-2
(Fisher Scientiﬁc; Pittsburgh, PA), and 1% penicillin/
streptomycin. Fibroblasts were grown as primary cul-
tures in 10% FBS containing DMEM with 1% penicillin/
streptomycin and 2% glutamine.
2.2. Generation of a recombinant adenovirus carrying the
full-length human REP-1-encoding cDNA
The full-length human REP-1 cDNA was assembled
by ligating the appropriate portions of clones 864 and
734 (generously provided by Dr. Jose van den Hurk (van
Bokhoven et al., 1994b)) after AﬂIII digestion. An ini-
tiation codon was introduced via polymerase chain
reaction (PCR; using sense primer: 50-ATGGCGGA-
TACTCTCCCTTCGG-30 and antisense primer: 50-AC-
CTGTTCCACTCGTCCTTCTC-30) and the full length
cDNA was cloned into the TA cloning vector (Invitro-
gen, Carlsbad, CA). The 2.5 kb cDNA was inserted
into pBluescript II KSðþÞ (Stratagene) and then sub-
sequently cut with Sma1 and Kpn1 and cloned
into EcoRV/Kpn1-cut Ad.CMVLink1 (provided by
J. Wilson), which placed REP-1 under control of the
cytomegalovirus (CMV) enhancer/promoter sequence
and the SV40 poly(A) sequence (Fig. 1) (Bennett et al.,
1996).
The recombinant adenovirus Ad.REP-1 was gen-
erated through homologous recombination with the
pAd.CMV-Link.1-derived plasmids and Ad5 strain
dl7001. This strain is deleted of E1 and the majority of
the E3 region (3.2 kb). Recombinants were obtained in
293 cells and were identiﬁed by Southern blot analysis.
The recombinant adenovirus was ampliﬁed, puriﬁed,
and titered to 1012 particles/ml as described (Bennett,
Zeng, Gupta, & Maguire, 2000). Adenoviruses were
screened for the presence of contaminating wild type
virus as described (Bennett et al., 1998). No contami-
nants were detected. The same stocks of adenoviruses
were used for all experiments. All manipulations of
adenoviral vectors were done according to institutional
and national biosafety restrictions.
2.3. Infection of ﬁbroblasts and transformed lymphocytes
with Ad.REP-1
Fibroblasts and lymphoblasts from individuals with
CHM and their relatives were plated in 100 mm culture
plates in an enriched media as described above. The cells
were grown till they reached 70% conﬂuency. At that
time, the percentage of serum was reduced from 10% to
2% to increase the eﬃciency of infection with Ad.REP-1.
Two microlitres of experimental or control virus were
added to the 100 mm plates providing exposure of 10
plaque-forming units per cell. Cells were maintained at
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37 C for 25–40 h. The cells were then harvested for
Western blots or immunostaining.
2.4. Protein studies
2.4.1. Western analysis
Western analysis was performed to evaluate presence
of the REP-1 protein. Frozen cell pellets were thawed,
resuspended in three volumes of lysis buﬀer (50 mM
Tris–Cl pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 5 mM
DTT, 0.5 M phenylmethylsulfonyl ﬂuoride, 5 lg/ml pep-
statin, 5 lg/ml aprotinin and 5 lg/ml leupeptin) and
mechanically disrupted by serial passages through a 21-
gauge needle. The lysate was spun at 100; 000 g for 1 h.
The pellet was discarded and the supernatant loaded on
a continuous 8% SDS-PAGE gel. Separated proteins
were transferred to PVDF membrane using a Hoeﬀer
transfer apparatus (2 h at 500 mA). The membranes
were allowed to dry and were blocked for 1 h with 5%
skimmed milk in incubation buﬀer (phosphate-buﬀered
saline (PBS), 0.2% Tween-20). The membranes were
then incubated with either 2F1 (1:1000) or J905 (1:5000)
Fig. 1. Construct used to generate recombinant virus carrying REP-1.
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antibodies diluted in incubation buﬀer. J905 is a rabbit
polyclonal antibody directed against recombinant rat
REP-1 (Forsythe et al., 1997). J905 recognizes both
human REP-1 (CHM) and REP-2 (CHML) proteins.
2F1 is a mouse monoclonal antibody which recognizes
human REP-1 only (Alexandrov et al., 1994). The im-
munogen used to generate 2F1 was a fusion protein
consisting of glutathione-S-transferase fused to the C-
terminal 415 amino acids of human REP-1 (Alexandrov
et al., 1994; MacDonald, Mah, Ho, Lewis, & Seabra,
1998). After washing, blots were incubated with the
secondary antibody peroxidase-labeled goat anti-rabbit
(for J905, Dako) or sheep anti-mouse antibody (for 2F1,
Amersham) diluted 1:10,000 in the incubation buﬀer and
developed using the Supersignal West Pico Chemilumi-
nescent Substrate (Pierce Chemical Co., Rockford, IL)
according to the manufacturers directions.
2.5. Immunoﬂuorescent staining of ﬁbroblasts/lympho-
blasts
Cells were plated in six-well plates containing sterile
22 mm2 coverslips, grown until they reached 70% con-
ﬂuency and infected as describe above. Lymphoblasts
were infected with Ad.Rep-1 in 2% FBS containing
DMEM or RPMI at an MOI of 30 and cultured another
24–40 h. Control cells were infected with Ad.LacZ. At
the end of infection, the media was aspirated, cells wa-
shed with PBS, and ﬁxed for 10 min with 4% para-
formaldehyde. After three washes, the cells were
permeabilized with 0.2% Triton in PBS, blocked with
3% BSA in PBS for 2 h and incubated with primary
antibody (J905 or 2F1) for 2 h. After washing, second-
ary antibody (FITC labeled goat anti-rabbit for J905
and FITC-labeled goat anti-mouse for 2F1; Jackson
Immunoresearch, diluted 1:1000) was applied to the cells
for an hour. After washing, cells were counterstained
with Hoechst stain and mounted on slides using citiﬂuor
(Ted Pella Inc.). Fluorescence was observed under a
Leica DMRE Microscope (Leica Microsystems, Inc.;
Deerﬁeld, IL) equipped with FITC and rhodamine ﬁl-
ters. Images were acquired digitally using OpenLab
software (Improvision).
2.6. Prenylation assay
Assays for the ability of the transgenic REP-1 protein
to assist in the prenylation reaction were performed as
described by Seabra and James (1999). Brieﬂy, experi-
mental and control ﬁbroblasts and lymphoblasts in-
fected with Ad.REP-1 were harvested 24–40 h after
infection and stored at )80 C until use. Reactions were
performed using tritiated all-trans-geranylgeranyl pyro-
phosphate (Dupont-New England Nuclear) as a prenyl
donor, recombinant Rab geranylgeranyl transferase and
increasing concentration of lysate from the infected
cells. Recombinant REP-1 was used in place of cell ly-
sate as a positive control. Incorporation of radiolabeled
prenyl groups into protein was determined by ethanol/
HCl precipitation and collection of precipitated protein
onto glass-ﬁber ﬁlters by vacuum ﬁltration. Reactions
were performed in duplicate.
3. Results
3.1. REP-1 (but not REP-2) is absent from the cells
harvested from individuals with Choroideremia
Western analysis using a monoclonal a-REP-1 anti-
body (2F1) revealed a single protein of 95 kDa in car-
riers but not in aﬀected individuals (data not shown and
Fig. 3). A truncated protein (which, if present, was
predicted to be 84 kDa for CPF1) was not detected.
REP-2, detected with antibody J905, was present in both
aﬀected individuals and carriers (Fig. 3 and data not
shown).
3.2. Ad.REP-1 infection of cultured cells from individuals
with CHM results in immunohistochemically identiﬁable
REP-1
To conﬁrm that the Ad.REP-1 is able to deliver REP-
1 to cells lacking this protein, lymphoblasts and ﬁbro-
blasts from individuals with CHM were exposed to this
virus and evaluated for immunoﬂuorescence evidence
of REP-1 expression. Immunostaining was performed
using antibody 2F1. High percentages of lymphoblasts
and ﬁbroblasts infected with the virus possessed immu-
nohistochemically identiﬁable REP-1 (Fig. 2B, D; 30%
and 40%, respectively). Only background levels of ﬂu-
orescence were detected in control Ad.LacZ-infected
cells (Fig. 2A,C). Fibroblasts were infected more eﬃ-
ciently with recombinant adenovirus than lymphoblasts
(compare 2B and D) and expressed REP-1 at higher
levels. This was true for cells from patients with both the
premature termination mutation and the deletion (data
not shown). In both ﬁbroblasts and lymphoblasts, REP-
1 was localized to the cytosol.
3.3. Western analysis conﬁrms that CHM cells exposed to
Ad.REP-1 possess the REP-1 protein
Protein expression after infection of wildtype and
CHM-aﬀected human ﬁbroblasts was analyzed by
Western analysis as shown in Fig. 3. Identity of REP-1
and REP-2 proteins was conﬁrmed by probing with
antibody J905, which recognizes REP-1 and REP-2
(lanes 1–4) and with antibody 2F1, which recognizes
REP-1 only (lanes 5–7). As expected, REP-2 protein was
identiﬁed in both CPF1 and CPF2 (lanes 2–4) regardless
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of treatment. As seen in lanes 2, 4, 5 and 7, infection of
ﬁbroblasts from both CPF1 and CPF2 with Ad.REP-1
results in production of REP-1 protein. The size of the
REP-1 control protein (lane 1) is higher than that de-
tected in the Ad.REP-1-treated ﬁbroblasts due to pres-
ence of a ‘‘his’’ tag in the former. Treatment with
Ad.REP-1 has minimal eﬀect on levels of REP-2 (com-
pare lanes 3 and 4). Treatment of ﬁbroblasts with
Ad.LacZ does not result in production of REP-1 (lanes
3, 6 and data not shown). Similar results were detected
Fig. 2. Representative results of immunoﬂuorescence analysis of REP-1 after in vitro delivery of Ad.REP-1 to cells of individuals with CHM. (A, B)
Lymphoblasts from individual CPF1 (with the Arg555!stop mutation). (C, D) Fibroblasts from individual CPF2 (with a 250 kb deletion in the
CHM locus). (A, C) Background ﬂuorescence is observed in control cells exposed to Ad.LacZ (B, D). Immunoﬂuorescent cells are observed after
treatment with Ad.REP-1.
Fig. 3. REP-1 is produced in ﬁbroblasts from an individual with CHM
after treatment with Ad.REP-1. Protein expression after infection of
wildtype and CHM-aﬀected human ﬁbroblasts was analyzed by
Western analysis. Identity of REP-1 and REP-2 proteins was con-
ﬁrmed by probing with antibody J905, which recognizes REP-1 and
REP-2 (lanes 1–4) and with antibody 2F1, which recognizes REP-1
only (lanes 5–7). Total protein from ﬁbroblasts from individual CPF2
was loaded in lanes 3, 4, 6 and 7 and from individual CPF1 in lanes 2
and 5. Protein was loaded after infection with Ad.REP-1 (lanes 4, 5, 7)
or with Ad.LacZ (lanes 3 and 6). Lane 1 contains recombinant his-
tagged REP-1. Infection with Ad.REP-1 results in production of REP-
1 protein (lanes 2, 4) but has minimal eﬀect on levels of REP-2
(compare lanes 3 and 4).
Fig. 4. REP-1 function is restored through treatment with Ad.REP-1.
Rab GGTase activity was measured in extracts derived from ﬁbro-
blasts from individual CPF2 as described under Section 2. Baseline
levels of Rab GGTase activity are observed in control cells. Cells in-
fected with Ad.REP-1 possessed high levels of Rab GGTase activity.
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in lymphoblasts (data not shown) but signal was much
reduced, likely due to reduced infectability of these cells
(see above).
3.4. REP-1 function is restored in defective cells through
infection with Ad.REP-1
As shown in Fig. 4, mock-infected ﬁbroblasts from
patient CPF2 had only baseline levels of Rab GGTase
activity. In contrast, cells infected with Ad.REP-1 pos-
sessed high levels of Rab GGTase activity. The level of
activity increased with the amount of total protein used
in the assay. This demonstrates restoration of function
of REP-1 to the defective cells.
4. Discussion
We have demonstrated that adenovirus-mediated de-
livery of REP-1 to ﬁbroblasts and lymphoblasts of in-
dividuals with CHM results in rescue as measured
immunohistochemically, through Western blot analysis
and through functional assay. CHM is one of the few
retinal diseases in which rescue can be evaluated initially
in vitro using ﬁbroblasts and lymphoblasts. The work
presented here is the ﬁrst step in developing gene-based
therapies for CHM. Two ingredients must be made
available before photoreceptor rescue can be attempted
in vivo: (1) identity of the ocular cell types which nor-
mally express REP-1 and (2) an animal model for CHM.
It will also be helpful to be able to test rescue in ocular
tissue of carriers of and aﬀected individuals with CHM.
However, such tissue is rarely available.
Identity of the ocular cell type which normally ex-
presses REP-1 is important as strategies must be devel-
oped which will speciﬁcally target these cells. Clinically,
CHM is characterized by progressive degeneration of
the RPE, choriocapillaris and retina. The degeneration
causes a unique ophthalmoscopic appearance including
RPE changes and choroidal atrophy, conﬁrmed by ﬂu-
orescein angiography (see for example Forsythe et al.,
1997). These changes, which identify the RPE and
choroid to clinicians as suspects in the search for disease
pathogenesis, gave the disease its name.
The pathological changes observed clinically in CHM
may, however, represent secondary sequelae of the dis-
ease process. This may be analogous to the situation
with Stargardt disease, which was initially thought to be
a disease of the RPE but is now known to originate in
photoreceptors (Allikmets et al., 1997; Sun & Nathans,
1997). What we do know about the CHM disease pro-
cess is limited. Histopathologic studies of CHM are rare
and tissue from only one aﬀected individual has been
evaluated (Rodrigues et al., 1984). In that person, an
asymptomatic 19 year old, there was diﬀuse loss of RPE
and choroid. Results from histological studies of female
carriers suggest that the disease may originate in pho-
toreceptors and/or RPE cells. Disease is patchy in the
carriers, perhaps due to Lyonization of the X chromo-
some. The eye of one carrier showed areas with nor-
mal photoreceptors interspersed with areas with either
absent photoreceptors or photoreceptors reduced in
number and with shortened or absent outer segments,
presumably due to random X chromosome inactivation.
The RPE was abnormally thick and pigmented and had
atrophic regions. The choroid was only abnormal in
areas underlying abnormal photoreceptors (Flannery,
Bird, Farber, Weleber, & Bok, 1990). An eye of another
such female had alternating areas of RPE atrophy but
normal retina and choroid (Krill, 1977). In a third car-
rier, the primary abnormalities appeared to lie in pho-
toreceptors. In those, outer segments over the entire
retina were malformed and there were speciﬁc areas of
degeneration leading to complete loss of photoreceptors
(Ghosh, McCulloch, & Parker, 1988). More recently, an
immunohistochemical study in a carrier revealed pres-
ence of REP-1 protein in rod photoreceptors and this
may have been present in other retinal cells as well (Syed
et al., 2001). In summary, it is diﬃcult to identify the
original disease-causing cells from these studies, but
these appear most likely to be photoreceptors or RPE
cells––not choroidal cells. Finally, molecular biological
studies have also been performed in order to determine
the tissue origin of the disease. The results complement
those from histopathologic studies in suggesting that
REP-1 is normally expressed in the neural retina in
primates and perhaps at lower levels in the RPE and
choroid (Bernstein & Wong, 1998; Cremers, van de Pol,
van Kerkhoﬀ, Wieringa, & Ropers, 1990b; Desnoyers,
Anant, & Seabra, 1996).
In order to expedite development of a treatment for
CHM, it will be helpful to obtain an animal model. This
will aid in identifying the disease-causing cells. It will
also be critical for development of gene based strategies
aimed at rescue. Recently, van den Hurk and colleagues
reported development of a mouse model of CHM re-
sulting from disruption of the REP-1 gene. While this
animal model is not completely representative of the
human condition (there is lethality in male embryos),
heterozygous females and chimeras for the REP-1 mu-
tation develop photoreceptor degeneration (van den
Hurk et al., 1997). The RPE and choroid remain intact.
These ﬁndings provide convincing evidence that the
REP-1 mutation results in photoreceptor degeneration
and strong evidence that the disease originates in pho-
toreceptors. If the mutant REP-1 gene causes photo-
receptor disease, vectors such as adeno-associated virus
or lentivirus may be eﬀective at delivering a gene
which will provide rescue. These vectors are highly eﬃ-
cient at targeting photoreceptors and lead to stable
transgene expression (Auricchio et al., 2001; Bennett,
Duan, Engelhardt, & Maguire, 1997; Bennett et al.,
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1999; Dudus et al., 1999; Zuﬀerey, Nagy, Mandel, Nal-
dini, & Trono, 1997). If it becomes necessary to target
RPE cells, it may be advisable to evaluate rescue using
adenovirus-based vectors, or AAVs produced with spe-
ciﬁc capsid serotypes so as to more eﬃciently target this
cell type (Auricchio et al., 2001; Bennett, Wilson, Sun,
Forbes, & Maguire, 1994; Li et al., 1994). Lentiviral
vectors may also be eﬃcacious (Auricchio et al., 2001).
In summary, the results reported here describe rescue
of defective ﬁbroblasts and lymphoblasts from humans
with CHM. This leads naturally to the question of
whether such a treatment, tailored to ocular tissue,
would be eﬀective in preventing or slowing retinal de-
generation in such patients. Given the progress in un-
derstanding the molecular bases and pathogenic
mechanisms involved in this disease, we believe that this
approach is very exciting and may lead to a viable
treatment for the blinding disease, CHM.
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